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Abstract
Aim and background To assess drug-related problems in
patients with liver cirrhosis by investigating the prevalence
of inadequately dosed drugs and their association with ad-
verse drug reactions (ADRs) and hospitalizations.
Methods This was a cross-sectional retrospective study
assessing the dose adequacy of drug treatment of 400 cir-
rhotic patients at hospital admission based on the authors’
own previous studies and standard literature. The prevalence
of total and preventable ADRs and of hospitalizations due to
preventable ADRs was determined.
Results Of all 1653 drugs prescribed (median 4 per patient),
336 (20 %) drugs were inadequately dosed in 184 patients.
Overall, 210 ADRs (78 % preventable) occurred in 120
patients. Sixty-nine ADRs (33 % of all ADRs) were associ-
ated with inadequate drug dosing in 46 patients, of which
68 % were preventable. Nonsteroidal anti-inflammatory
drugs and psycholeptics in particular frequently caused pre-
ventable ADRs associated with inadequate drug dosing.
Inadequate drug dosing was more frequently associated with
ADRs than adequate drug dosing, and patients receiving
inadequately dosed drugs were more frequently admitted
to the hospital due to ADRs. Hospitalization of patients
receiving inadequately dosed drugs that caused preventable
ADRs resulted in 94 additional hospital days.
Conclusion In this retrospective study, inadequate drug dos-
ing was associated with an increased frequency of ADRs,
hospital admissions and hospital days in cirrhotic patients.
We therefore conclude that the careful dosing of critical
drugs is important in patients with liver cirrhosis.
Keywords Liver cirrhosis . Dose adjustment . Adverse drug
reactions . Drug–drug interactions
Introduction
The elimination of the majority of drugs on the market de-
pends on liver function. About two-thirds of the drugs on the
Swiss market have an extrarenal dose fraction (Q0) of >0.5
and are thus cleared mainly by the liver. Most patients with
liver cirrhosis have an impaired hepatic handling of such
drugs, depending on the severity of cirrhosis [1, 2].
In patients with liver cirrhosis, hepatic extraction can be
impaired, leading to a substantial increase in the bioavail-
ability of drugs that have a high hepatic extraction in healthy
subjects. This is mainly due to an impaired exposure of the
hepatocytes to blood because of extra- and intrahepatic
shunts [3]. Furthermore, the access of drugs to hepatocytes
may be diminished in cirrhotic livers due to capillarization
of the sinusoidal endothelium [4].
In addition to this increased bioavailability of drugs,
hepatic clearance of most drugs mainly metabolized
and/or excreted by the liver is reduced in patients with
liver cirrhosis. For drugs with a high hepatic extraction,
this is mainly due to impaired blood flow across the liver
[1, 2, 5, 6]. For drugs with a low hepatic extraction,
metabolism by phase I enzymes, in particular cytochrome
P450 enzymes (CYP), is the critical factor [2]. Several
investigations have shown that the protein content and/or
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the activity of the most important CYPs is reduced in
cirrhotic livers [1, 2, 7]. CYPs appear to be more sensi-
tive to liver cirrhosis than phase II enzymes, such as
uridine diphosphate glucuronosyltransferase [1].
The free fraction and possibly also the free concen-
tration of highly albumin-bound drugs are increased in
patients with hypoalbuminemia, such as those with liver
cirrhosis [2]. This may change the kinetic behavior of
such drugs, which may be associated with adverse drug
reactions. However, not only pharmacokinetic alterations
but also pharmacodynamic aspects must also be consid-
ered as a potential reason for adverse drug reactions
(ADRs) in this patient population. For example, nonste-
roidal anti-inflammatory drugs (NSAIDs) should be
avoided by such patients due to the risk for impaired
renal perfusion, eventually leading to renal failure [2].
Similarly, susceptibility to central adverse effects of
opiates, such as morphine [8], and benzodiazepines [9]
is increased in patients with liver cirrhosis.
Due to these pharmacokinetic and pharmacodynamic
alterations pharmacotherapy in patients with liver cirrhosis
is complex. The high inter-individual variability of these
alterations renders pharmacotherapy in cirrhotic patients
even more complicated [1, 2].
We recently published a cross-sectional retrospective
study presenting demographic data, medication patterns,
potential drug–drug interactions and ADRs in 400 pa-
tients with liver cirrhosis admitted to the University
Hospital of Basel [10]. We found a high prevalence of
potential drug–drug interactions and ADRs in this group
of patients at hospital admission. In current study
presented here, we focused on the quality of dose ad-
justment in this population and estimated the excess of
ADRs and hospitalization days in patients receiving
inadequate drug dosing at hospital admission.
Materials and methods
Patients
This work is based on a previously published, descrip-
tive, cross-sectional, retrospective study that investigated
diagnoses, medication patterns, potential drug–drug in-
teractions and ADRs in 400 cirrhotic patients at hospital
admission[10]. Each patient received a median (range)
of five (0–18) drugs, of which three (0–16) were pre-
dominantly hepatically eliminated. A total of 200 ADRs
with a definite, probable or possible causality-rating
were detected in 112 patients (28 %); these ADRs were
associated mainly with spironolactone, torasemide, furo-
semide or ibuprofen. In 86 (21.5 %) patients, 132 po-
tential drug–drug interactions were detected.
Drug categorization
The drugs were classified by their Q0 and their hepatic
extraction (Eh) into five categories. Drugs with a Q0 of
≥0.5 were considered to undergo mainly hepatic elimina-
tion. For drugs with a Q0 of ≥0.5, the Eh was obtained from
the literature (either published as hepatic extraction or cal-
culated from the oral bioavailability and the intestinal ab-
sorption, with oral bioavailability defined as the portion of
the drug reaching the systemic circulation after oral inges-
tion; it can be limited by intestinal absorption and by the
hepatic first-pass effect). If Eh could not be obtained from
the literature, it was estimated using Eq. 1:
Eh ¼ Clsys  Q0Qplasma
ð1Þ
where Clsys is the systemic clearance (L/h), Q0 the extrarenal
dose fraction of a specific drug and Qplasma is the hepatic
plasma flow (approx. 43 L/h) [11].
The drugs were further categorized according to Eh into
the three categories of high hepatic extraction drugs (cate-
gory 1), intermediate hepatic extraction drugs (category 2)
and low hepatic extraction drugs (category 3). Drugs with a
Q0 of <0.5 are excreted mainly by the kidney (category 4).
Category 5 refers to drugs with an unknown Q0 and/or Eh.
For further information on this classification, see Fig. 1 and
the publications of Delco et al. [2], Tchambaz et al. [12] and
Schlatter et al. [13].
Dose assessment and ADRs
Each patient’s dose at hospital admission was compared to
published dosing recommendations for patients with liver
cirrhosis (Fig. 1; [2, 12, 13]) and assessed using a prototypal
internal drug database. This database was constructed as
described in our previous publications on medication in
liver cirrhosis [2, 12, 13]. The recommendations on dosing
in patients with liver cirrhosis compiled in this database are
based on published kinetic studies for individual drugs and
on the recommendations provided in the Physician’s Desk
Reference (PDR) [14], Micromedex® [15] and/or the Swiss
Drug Register [16].
All patients included in the study were on long-term
medication and used their maintenance dose at hospital
entry; initial doses were therefore not considered in our
analysis. According to the general recommendations [2,
12, 13], the maintenance dose for category 1, category 2
or category 3 drugs should be reduced by approximately
50–75, 50 or 0–50 %, respectively, in patients with liver
cirrhosis (Fig. 1). Since up-titration according to clinical
effect and tolerability is recommended for most drugs, doses
that exceeded the general recommendations had to be
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judged individually using the recommendations of the
internal database described above. This database provides
dosing recommendations adjusted to the severity of liver
disease according to the Child class. Accordingly, for
each dose assessed, characteristics of the individual pa-
tient (in particular the severity of liver disease), as well
as of the drug administered (in particular, the existence
of dose-dependent, clinically relevant ADRs) were taken
into account. For drugs which can be monitored by
specific tests (e.g. international normalized ratio for
phenprocoumon, blood glucose for insulin and oral di-
abetics, serum levels), these values were taken into ac-
count for judging the dose.
All drugs contraindicated or prescribed in a dose not
corresponding to the internal database described above were
considered as “inadequately dosed drugs” and were further
analyzed. We assessed how many patients received inade-
quate drug dosing and which category and Anatomical
Therapeutic Chemical (ATC) codes were involved.
We identified the ADRs associated with inadequately
dosed drugs and classified each ADR as either a type A
(dose-dependent, considered to be preventable) or type B
ADR (dose-independent, considered not to be prevent-
able). We then assessed the prevalence of total as well
as preventable ADRs per drug category. We also investigated
the impact of inadequately dosed drugs on mortality. For
preventable ADRs associated with inadequate drug dosing
as the reason for hospitalization, the excess hospitalization
days were determined. Finally, the discontinuation rate of
drug treatments at hospital entry was assessed as well as the
reasons for discontinuation, in particular inadequate drug
dosage and ADRs.
Risk assessment for inadequately administered drugs
To investigate whether inadequate drug dosing was associ-
ated with an increased risk for ADRs, we calculated the
relative risk for developing ADRs according to the ATC
drug category code in patients receiving inadequate drug
dosing compared to patients who did not receive inadequate
drug dosing and expressed it as an odds ratio (OR). A
significance level of 5 % was chosen.
Contraindicated drugs
The Physicians' Desk Reference (PDR) [14] was consulted
to check if the prescribed drugs were formally contraindicated
in patients with liver disease. Drugs not listed in the PDRwere
checked in Micromedex® [15], and drugs listed neither in
the PDR nor in Micromedex® were judged by means of
our internal database which is based on data retrieved
from published studies. According to our database,
NSAIDs are contraindicated in patients with liver cirrhosis
due to an increased risk for ADRs, in particular gastroin-
testinal bleeding and/or renal failure [2, 17, 18]. This
assessment is supported by the results of our previous
study, showing a poor tolerability of these drugs by pa-
tients with liver cirrhosis [10]. We also investigated the
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Fig. 1 Classification and dosage recommendations of drugs in patients
with liver cirrhosis. Drugs were classified into 5 categories (CAT)
according to their pharmacokinetic parameters Q0 (extrarenal dose
fraction) and Eh (hepatic extraction). If published data for Eh were
not available, Eh was estimated according to Eq. (1) in Materials and
methods. If bioavailability after oral administration (F) was available,
intestinal absorption was also taken into account to estimate Eh. CAT 1
High hepatic extraction drugs, CAT 2 intermediate hepatic extraction
drugs, CAT 3 low hepatic extraction drugs, CAT 4 renal elimination
drugs, CAT 5 drugs with unknown elimination pathway, IDpo initial
dose administered orally, MD maintenance dose
Eur J Clin Pharmacol (2013) 69:1565–1573 1567
question of whether ADRs were more frequently associat-
ed with contraindicated than with not contraindicated
drugs.
Proton pump inhibitors and bacterial infections
Recently published studies suggest that proton pump
inhibitors may be associated with an increased risk for
spontaneous bacterial peritonitis and/or Clostridium
difficile infections in patients with liver cirrhosis [19,
20]. Since we did not address the association between
proton pump inhibitors and these infections in our
previous study, we investigated it in the current one.
We considered these ADRs to be dose independent
based on our analysis.
Results
Drug categories at hospital admission
At hospital admission, the 400 patients with liver cir-
rhosis [Child categories: A, 70 (18 %) patients; B, 157
(39 %) patients; C, 173 (43 %) patients] had 1653
prescriptions (median 4 drugs per patient, range 0–15),
excluding vitamins and minerals. In terms of drug cat-
egories, most abundant drugs were those with a low
(29.4 %) or high (27.4 %) hepatic extraction, followed
by drugs with intermediate hepatic extraction (19.2 %),
and drugs with mainly renal (12.3 %) or unknown
elimination (11.7 %) (Fig. 2). Details on those drugs
with hepatic elimination, for example, individual drug
classes, are presented in our previous publication [10].
Dose assessment and ADRs
Overall, 336 (20.3 %) of all drugs (47.6 % of category 2,
20.1 % of category 4, 18.1 % of category 3, 10.6 % of
category 1, 4.1 % of category 5; Fig. 2) were assessed to have
been dosed inadequately in 184 patients. Thirty-six of these
drugs were contraindicated in patients with liver cirrhosis, and
300 were administered at inappropriately high doses. The
majority of drugs (68.4 % of all drugs; 89.4 % of category
1, 81.7 % of category 3, 80.0 % of category 4, 51.7 % of
category 2, 2.5 % of category 5) were dosed adequately, and
11.1 % of all drugs could not be assessed regarding dosing
(not assessable drugs). According to the ATC code, the
drugs most frequently inadequately dosed were those for
the alimentary tract and metabolism (ATC A; n=137),
nervous system (ATC N; n=80), cardiovascular system
(ATC C; n=62) and musculo-skeletal system (ATC M;
n=31) (Fig. 3). The ATC drug classes most often involved
in ADRs were AO2 (drugs for acid-related disorders),
A10B (oral blood glucose-lowering drugs), M01A (non-
steroidal anti-inflammatory and antirheumatic products),
N05C (hypnotics and sedatives) and N02B (other analgesics
and antipyretics).
In total, 210 ADRs (164 preventable reactions, 78.1 % of
all ADRs) occurred in 120 patients [median 1 (range 1–5)
per affected patient]. Forty-seven ADRs (22 % of all ADRs)
occurred in Child A patients, 68 (33 %) in Child B patients
and 95 (45 %) in Child C patients. Of all ADRs, 69 [29 % of
all ADRs; 47 (68 %) of them preventable) were associated
with inadequate drug dosing in 46 patients. Fourteen of
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these ADRs (20 %) occurred in Child A patients, 21 (31 %)
in Child B patients and 34 (49 %) in Child C patients.
ADRs associated with inadequate drug dosing are listed
in Table 1. In particular, NSAIDs and psycholeptics and
drugs for acid-related disorders were frequently involved
in these ADRs. Low, intermediate and high hepatic extrac-
tion drugs were associated with 29, 28 and eight ADRs
caused by inadequate drug dosing, respectively. Seven of
the ADRs were due to a drug–drug interaction.
Twenty-four ADRs in 24 patients were the reason for hos-
pital admission. Of these 24 ADRs, six (25 %), six (25 %) and
12 (50 %) occurred in Child class A, B and C patients,
respectively. Noticeably, patients with inadequately dosed
drugs (n=20, 10.9 %) were more frequently admitted to the
hospital due to an ADR than patients with adequately
dosed/not assessable drugs (n=4, 1.9 %). ADRs leading to
hospital admission were spontaneous bacterial peritonitis as-
sociated with omeprazole, esomeprazole or pantoprazole;
Clostridium difficile infection associated with omeprazole or
esomeprazole; gastrointestinal bleeding associated with
diclofenac, ibuprofen, piroxicam or phenprocoumon; coma
associated with midazolam; worsening of ascites associated
with ibuprofen. Of the 20 ADRs leading to hospital admission
associated with inadequate drug dosing, six were considered to
be preventable. These six patients stayed in the hospital for a
total of 94 days.
As shown in Fig. 4, overall, ADRs occurred more fre-
quently in cases of inadequate drug dosing than in cases of
adequately dosed drugs (overall: 20.5 vs. 13.5 % of the
prescribed drugs; preventable: 14.0 vs. 10.6 %). Surprising-
ly, this was not the case for all drug categories. For example,
ADRs were less frequent in category 1 drugs that were
dosed inadequately compared to those dosed adequately
(16.7 vs. 20.0 %, respectively); the same was true for drugs
primarily eliminated renally (category 4; 12.2 vs. 25.2 %,
respectively). In the other drug categories (categories 2, 3, 5),
more ADRs occurred in cases of inadequate drug dosing
compared to adequate drug dosing, with the difference being
Table 1 Adverse drug reactions associated with inadequate drug dosing
Drug class
(ATC code)
Drugsa Preventable ADRsa Other ADRsa
Anti-inflammatory
and antirheumatic
products (M01)
Ibuprofen (11b), diclofenac
(7b), mefenamic acid (6b),
piroxicam (1b)
Gastrointestinal hemorrhage/ulcer
(12b; 1 DDI), anemia (3b),
worsening of ascites (2b),
hyperkalemia (1b; 1 DDI),
reduction of creatinine clearance
(1b), psychomotor agitation (1b),
epistaxis (1b; 1 DDI)
Thrombocytopenia (2b),
leucopenia (1b)
Psycholeptics (N05) Zolpidem (6), diazepam
(2b, 1), midazolam (2),
pipamperon (1)
Somnolence (3), confusion (1b, 2),
gait disorder (1), mental deceleration
(1; 1 DDI), fall (1b)
Somnambulism (1),
elevated ALT (1)
Drugs for acid related
disorders (A02)
Omeprazole (3), esomeprazole (3),
pantoprazole (2), lansoprazole
(1),
Spontaneous bacterial
peritonitis
6), Clostridium difficile
infection (2), elevated ALT (1)
Diuretics (C03) spironolactone (6),
torasemide (2)
Reduction of creatinine clearance (3),
hyperkalemia (2; 1 DDI),
hyponatremia (1)
Anemia (1), diarrhea (1)
Drugs used in diabetes (A10) Metformin (3),
rosiglitazone (2)
Loss of appetite (1), diarrhea (1),
heart failure (1)
Thrombocytopenia (1),
hyperbilirubinemia (1)
Calcium channel blockers
(C08)
Amlodipine (4) Edema (2), dyspnea (1) Hyperbilirubinemia (1)
Agents acting on the renin–
angiotensin system (C09)
Ramipril (2),
losartan (2)
Syncope (1), hyperkalemia (1),
hypotension (1)
Eosinophilia (1)
Antithrombotic agents (B01) Phenprocoumon (1) INR increased (1)
Antineoplastic agents (L01) Doxorubicin (1) Neutropenic fever (1; 1 DDI)
Analgesics (N02) Acetylsalicylic acid (1b) Gastrointestinal ulcer (1b)
Other nervous system drugs
(N07)
Methadone (1) Torsade de pointes (1; 1 DDI)
ATC, Anatomical Therapeutic Chemical classification system; ADR, adverse drug reaction; ALT, alanine aminotransferase; AP, alkaline phospha-
tase; DDI, drug–drug interaction
a Number given in parenthesis is the number of ADRs
b Contraindicated drug/ADRs associated with contraindicated drug
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most pronounced in category 3 drugs (33.0 vs. 14.1 %,
respectively) followed by category 2 drugs (18.5 vs.
12.2 %, respectively). For category 5, we compared the drugs
which are contraindicated or not recommended in liver
cirrhosis with the other drugs in this group (adequately
dosed drugs and not assessable drugs) and found
that ADRs occurred more frequently with drugs that
are contraindicated/not recommended in liver cirrhosis
(12.5 vs. 4.9 %).
The only ATC group associated with a statistically
significant increased risk for ADRs in the case of inad-
equate drug dosing was the musculo-skeletal system
group [ATC M: OR 11.1, 95 % confidence interval
(CI) 2.5–66.5; Fig. 5], which contains the NSAIDs.
At hospital admission, the likelihood that treatment with
inadequately dosed drugs associated with an ADR would be
stopped [total 37/50 (74.0 %); category 4 and 5, 100 %;
category 3, 76.2 %; category 2, 70 %; category 1, 60.0 %)
did not differ from that with adequately dosed drugs asso-
ciated with an ADR [total 98/131 (74.8 %); category 5,
100 %; category 4, 88.5 %; category 1, 77.6 %; category
2, 76.5 %; category 3, 60.5 %). Treatment with inadequately
dosed drugs not associated with ADRs was less often
stopped at hospital admission [total 89/286 (31.1 %); cate-
gory 5, 57.1 %; category 2, 35.1 %; category 4, 28.9 %;
category 3, 26.9 %; category 1, 23.3 %).
An increased mortality rate was observed in patients with
ADRs (see below). Adequate dosing, however, had only a
minor influence on mortality. In patients with ADRs, mor-
tality was similar in patients with inadequately dosed drugs
and those with adequately dosed/not assessable drugs (24.5
versus 23.9 %, respectively). In comparison, in patients
without ADRs, mortality rates were 14.6 % in patients
receiving inadequate drug dosing and inadequate dose
dosing/not assessable drugs.
Contraindicated drugs
Of all drugs, 36 (2.2 %) were contraindicated in patients
with liver disease [ibuprofen (12), diclofenac (9),
mefenamic acid (5), diazepam (3), atorvastatin (2),
acemetacin (1), piroxicam (1), analgesic acetylsalicylic
acid (1), methyldopa (1), pravastatin (1)]. The drug cat-
egories involved were category 1 drugs with high hepatic
extraction (e.g. acetylsalicylic acid, atorvastatin, pravastat-
in), category 2 with intermediate hepatic extraction (e.g.
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Fig. 4 Number of prescriptions, total number of adverse drug reac-
tions (ADRs) and number of preventable (Type A) ADRs stratified per
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since ADRs caused by more than one drug (e.g. one inadequately as
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diclofenac) and category 3 with low hepatic extraction (e.g.
acemetacin, ibuprofen, piroxicam, diazepam, zopiclone,
methyldopa), as well as category 5 drugs with unknown
elimination (e.g. mefenamic acid).
In total, these drugs caused 28 ADRs (indicated with a
superscript 'b' in Table 1). The most frequent ADRs were
gastrointestinal hemorrhage/ulcer associated with NSAIDs.
Related to prescriptions, approximately sevenfold more
ADRs (7.7-fold more preventable ADRs) occurred due to
treatment with contraindicated drugs as compared to non-
contraindicated drugs.
Proton pump inhibitors and bacterial infections
Eighteen spontaneous bacterial peritonitis and six Clostridium
difficile infections occurred in the study population, of which
nine and three, respectively, were associated with proton
pump inhibitors. Patients ingesting proton pump inhibitors
suffered more frequently from spontaneous bacterial peritoni-
tis or Clostridium difficile infection than patients not taking
proton pump inhibitors (7.8 vs. 4.9 %, respectively).
Additionally, inadequately dosed proton pump inhibitors
were more frequently associated with such infections
than adequately dosed proton pump inhibitors (8.9 vs.
6.3 %, respectively). Six hospitalizations were due to
spontaneous bacterial peritonitis or Clostridium difficile
infection associated with inadequately dosed proton
pump inhibitors.
Discussion
Drug dosing in 400 cirrhotic patients at hospital entry was
assessed using our own recommendations [2, 12, 13], the
recommendations provided by Micromedex® [15] and the
respective product information [14]. Approximately three-
quarters of all drugs (excluding vitamins and minerals) used
in this patient population have a predominantly non-renal
elimination, in most cases involving the liver. Approximate-
ly 20 % of the prescriptions were considered to be inappro-
priate due to an excessively high dose or a contraindication.
Inadequate drug dosing was more frequently associated with
ADRs (20.5 % of prescriptions) compared to adequate drug
dosing (13.5 % of prescriptions). Patients with inadequately
dosed drugs were more frequently admitted to hospital due
to an ADR (10.3 vs. 1.9 %) than patients with adequately
dosed drugs/not assessable drugs. Since most of the inade-
quately dosed drugs associated with ADRs were recognized
at hospital entry and the appropriate adjustments in therapy
taken, the duration of hospitalization and mortality rates
were not different between patients with or without inade-
quately dosed drug(s).
To the best of our knowledge, this is the first published
study in which the potential effect of dose adjustment on
drug-related problems in patients with liver cirrhosis is
reported. A major problem may be that, in contrast to
impaired renal function, no generally accepted dose recom-
mendations exist for patients with impaired liver function.
This is particularly true for older drugs where recommenda-
tions in the product information are often lacking or not
helpful (e.g. “drug should be used with caution”) and the
problem is shifted to the prescriber.
In comparison to our previous study involving the same
group of patients [10], the number of prescriptions in the
present study is lower due to the exclusion of vitamins and
minerals. Since precise pharmacokinetic data for vitamins
and minerals are usually not available, most of these sub-
stances would belong to category 5 with an unknown elim-
ination pathway, resulting in an overestimation of this drug
category (in our previous study, 17 % of all prescriptions
were vitamins and minerals [10]). Taking into account the
generally good tolerability of vitamins and minerals, we feel
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that their exclusion from our analysis is acceptable. The
number of ADRs is higher in the present study than in our
earlier study [10]. This is due to the inclusion of spontaneous
bacterial peritonitis and Clostridium difficile infections, which
were considered to be associated with proton pump inhibitors
[19, 20].
In our study, 20.3 % of all prescriptions were dosed inad-
equately in relation to liver function, and inadequately dosed
drugs were more frequently associated with ADRs than ade-
quately dosed drugs. This result was expected given that most
ADRs are dose dependent. Surprisingly, the number of ADRs
associated with inadequate drug dosing was not higher for
drugs with a high hepatic extraction (category 1) or
predominantly renal elimination (category 4) than for
adequately dosed drugs. It appears, therefore, that phy-
sicians are aware of the high-risk drugs in these patients
and of the necessity for dose adjustment in patients with
liver cirrhosis. A contributing factor may be that the
maintenance dose of such drugs can be adjusted according to
clinical effect and tolerability in each individual patient. For
certain drugs, the actual maintenance dose may therefore be
higher than that suggested by the recommendations. This is,
for example, the case for beta-blockers, which were the most
frequent category 1 drugs in our population (e.g. propranolol).
Therefore, the dosage of category 1 beta-blockers was
assessed only rarely as inappropriate (only in 3 of 109 cate-
gory 1 beta-blocker prescriptions).
The inadequate dosing of category 4 drugs was mainly
due to the prescription of metformin and the dosage of
ramipril. Metformin should be avoided in patients with liver
cirrhosis due to an increased risk for lactic acidosis, and
ramipril should be used only at a low dose, since hemody-
namic changes in patients with liver cirrhosis predispose
them for renal hypoperfusion and/or hypofiltration, possibly
leading to renal failure [2].
In our study, 78 % of all ADRs and 68 % of ADRs
associated with inadequate drug dosing were classified as
potentially preventable. These numbers correspond well
with the frequencies reported in a review published in
2007 [21], stating that 80 % (51–100 %) of adverse drug
events in hospitalized patients are potentially preventable.
The prevention of such events could be achieved by using
the lowest effective dose and by the elimination of drug–
drug interactions and other medication errors [21].
NSAIDs were by far the most often prescribed
contraindicated drugs in this population: of the 36
contraindicated drugs, 28 were NSAIDs. NSAIDs caused a
total 25 ADRs, of which 21 were considered to be preventable
and five were a reason for patient hospitalization. Cirrhotic
patients treated with a NSAID had a 50 % probability to
develop a severe ADR. In total, patients treated with a
contraindicated drug (including NSAIDs) had a sevenfold
higher risk to suffer from an ADR than patients without
contraindicated drugs. These figures highlight the importance
that this patient group avoids the use contraindicated drugs,
NSAIDs in particular. Interestingly, the use of NSAIDs in
cirrhotic patients is not contraindicated in the PDR or
Micromedex®, but it is by the Swiss Drug Register. Taking
into account the high frequency of the mostly severe ADRs
caused by NSAIDs (leading to hospitalization and, potentially,
death), NSAIDs should be considered to be contraindicated in
cirrhotic patients.
Interestingly, ADRs associated with inadequate drug
dosing were most frequently related to drugs causing
pharmacodynamic alterations in patients with liver cirrhosis;
the drug classes most often involved were NSAIDs,
sedatives/hypnotics and oral antidiabetics. While central ner-
vous system-depressing drugs bear an increased risk for hepat-
ic encephalopathy [2], oral antidiabetics may induce
hypoglycemia due to impaired drug metabolism and possibly
also impaired gluconeogenesis in patients with decompensated
liver cirrhosis [22].
Consistent with growing evidence from the literature
[19, 20], patients with proton pump inhibitors suffered
more frequently from spontaneous bacterial peritonitis or
Clostridium difficile infection in our study. Proton pump
inhibitors reduce gastric acid production, possibly
resulting in an impaired gastric barrier against enteric
pathogens [19]. An association of acidic suppression
with increased bacterial colonization and risk of infec-
tion has been observed [19, 23]. Physicians should be
aware of these possible ADRs and should very carefully
reflect on the indication for proton pump inhibitors in
patients with liver cirrhosis.
Our study has several limitations. The retrospective char-
acter only allowed us to include the data documented in the
medical records, which was not always complete. Further-
more, retrospective studies can generate hypotheses, but this
design is not suitable to draw firm conclusions. It has to be
realized, however, that not all aspects of the current study
could be investigated prospectively; for example, it would
be unethical to treat patients with contraindicated drugs.
In conclusion, the results of our study show that approx-
imately 20 % of the prescriptions in patients with liver
cirrhosis are inappropriate because of dosage and/or contra-
indication. Based on these results, we suggest that patients
with inappropriate prescriptions, especially those treated
with contraindicated drugs, are at a high risk for ADRs,
leading to a higher hospitalization rate—and the associated
higher costs—due to these ADRs. Careful dosing, especially
of drugs used for other indications than liver disease, and the
avoidance of contraindicated drugs are therefore mandatory
in this group of patients.
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